Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Show full item record

Permalink

http://hdl.handle.net/10138/306832

Citation

Lauseker , M , Bachl , K , Turkina , A , Faber , E , Prejzner , W , Olsson-Stromberg , U , Baccarani , M , Lomaia , E , Zackova , D , Ossenkoppele , G , Griskevicius , L , Schubert-Fritschle , G , Sacha , T , Heibl , S , Koskenvesa , P , Bogdanovic , A , Clark , R E , Guilhot , J , Hoffmann , V S , Hasford , J , Hochhaus , A & Pfirrmann , M 2019 , ' Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin ' , American Journal of Hematology , vol. 94 , no. 11 , pp. 1236-1243 . https://doi.org/10.1002/ajh.25628

Title: Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
Author: Lauseker, Michael; Bachl, Katharina; Turkina, Anna; Faber, Edgar; Prejzner, Witold; Olsson-Stromberg, Ulla; Baccarani, Michele; Lomaia, Elza; Zackova, Daniela; Ossenkoppele, Gert; Griskevicius, Laimonas; Schubert-Fritschle, Gabriele; Sacha, Tomasz; Heibl, Sonja; Koskenvesa, Perttu; Bogdanovic, Andrija; Clark, Richard E.; Guilhot, Joelle; Hoffmann, Verena S.; Hasford, Joerg; Hochhaus, Andreas; Pfirrmann, Markus
Contributor: University of Helsinki, HUS Comprehensive Cancer Center
Date: 2019-11
Number of pages: 8
Belongs to series: American Journal of Hematology
ISSN: 0361-8609
URI: http://hdl.handle.net/10138/306832
Abstract: Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known about the prognosis of these patients. Our aim was to identify prognostic factors for this cohort. We identified 283 patients in the EUTOS population-based and out-study registries that were diagnosed in advanced phase. Nearly all patients were treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was 8.2 years. When comparing patients with more than 30% blasts to those with 20-29% blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts (HR: 2.24, 95%-CI: [1.2-4.0], P = .008). We found that the blast count was the most important prognostic factor; however, age, hemoglobin, basophils and other chromosomal aberrations should be considered as well. The ELTS score was able to define two groups (high risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P <.001). Regarding the contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the 30% cut-off in this cohort. Based on our results, we conclude that a one-phase rather than a two-phase categorization of de novo advanced phase CML patients is appropriate.
Subject: WORLD-HEALTH-ORGANIZATION
CHRONIC MYELOGENOUS LEUKEMIA
TYROSINE KINASE INHIBITORS
2904 CML PATIENTS
RANDOMIZED CML
SURVIVAL
MANAGEMENT
IMATINIB
ERA
RECOMMENDATIONS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Lauseker_et_al_ ... _Journal_of_Hematology.pdf 1.373Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record